Over the past decade, GLP-1 RAs have emerged as a promising class of therapeutic agents, initially recognized for their role in glycemic control in type 2 diabetes mellitus.2Notably, agents such as liraglutide, semaglutide, exenatide, and tirzepatide have also been employed in the management of obesity, not only promoting weight loss but also offering beneficial metabolic effects on comorbid conditions such as hypertension and dyslipidemia.2 This evidence concerns the gene GLP1R and Hypertension.